Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance
09 sept. 2019 08h30 HE
|
Kitov Pharma Ltd.
Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor models of mice implanted with biopsies from patients (PDX)...
Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
03 sept. 2019 08h22 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference
29 août 2019 08h30 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal
16 août 2019 08h24 HE
|
Kitov Pharma Ltd.
- Orbimed, Pontifax and Arkin Holdings to deposit $3.5 million investment in Kitov in escrow- Progress facilitates the advance of activities in development of the oncology asset CM-24 TEL AVIV,...
Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority
14 août 2019 08h20 HE
|
Kitov Pharma Ltd.
Israeli Investigation of Kitov and certain officers has been terminated TEL AVIV, Israel, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage...
Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update
08 août 2019 08h20 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements
12 juil. 2019 17h11 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, July 12, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers
27 juin 2019 07h30 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, June 27, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class oncology therapies to overcome...
Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi™
10 mai 2019 09h20 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, May 10, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to...
Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference
09 mai 2019 08h30 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, May 09, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (the “Company” or “Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology...